BS
STRO icon

Banco Santander’s Sutro Biopharma STRO Stock Holding History

Banco Santander’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,000
Closed -$2.08M – 375
2022
Q2 		$2.08M Hold
40,000
– – 0.03% 212
2022
Q1 		$3.29M Buy
+40,000
New +$3.81M 0.04% 196

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Banco Santander's STRO Position: Q3 2022 in Review

Banco Santander sold out of Sutro Biopharma (STRO) in Q3 2022, closing a stake of 40,000 shares — an estimated $2.08M sold.

Banco Santander first reported a position in STRO in Q1 2022 and held it in 2 quarters. The position peaked at $3.29M in Q1 2022. 113 funds tracked by Wall St. Rank hold STRO as of Q3 2022.

  • Banco Santander reported no remaining Sutro Biopharma position as of Q3 2022 after selling out during the quarter.
  • Banco Santander sold 40,000 Sutro Biopharma shares in Q3 2022, an estimated $2.08M.
  • Banco Santander first reported a position in Sutro Biopharma in Q1 2022 and held it in 2 quarters.
  • Banco Santander's Sutro Biopharma position peaked at $3.29M in Q1 2022.
  • 113 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2022.

Based on Banco Santander's 13F filing for Q3 2022, filed 8 Nov 2022.